Literature DB >> 9581840

DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors.

Y Chen1, D Hu, D J Eling, J Robbins, T J Kipps.   

Abstract

We generated DNA expression vectors encoding the full-length neu cDNA (designated pNeuN), the neu extracellular domain (pNeuE), or the neu extracellular and transmembrane domains (pNeuTM). The 293 cells transfected with pNeuN or pNeuTM expressed the neu extracellular domain on the surface membrane, whereas 293 cells transfected with pNeuE secreted the extracellular domain of neu into the culture supernatant. We examined whether i.m. injection of either of these plasmids could induce protective immunity in FVB/N mice against the adoptive transfer of Tgl-1 cells, a neu-expressing tumor cell line generated from a mouse mammary tumor that spontaneously arose in a FVB/N neu-transgenic mouse. The i.m. injection of pNeuTM or pNeuE, and to a lesser extent pNeuN, induced protective immunity against a subsequent challenge with Tgl-1 cells in FVB/N mice. In addition, the coinjection of a plasmid encoding interleukin-2 (designated pIL-2) augmented the efficacy of each of the pNeu plasmids for inducing protective immunity. The plasmid pNeuTM seemed to be the most effective for inducing anti-neu antibodies. However, the generation of detectable anti-neu antibodies in response to any one of these pNeu plasmids was not enhanced by coinjection of pIL-2 and was not required for protective immunity against Tgl-1 cells. These studies demonstrate that DNA expression vectors encoding soluble or membrane-bound forms of neu lacking the cytoplasmic kinase domain can be effective in inducing protective antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9581840

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Strategies for improving responses to DNA vaccines.

Authors:  J S Boyle; I G Barr; A M Lew
Journal:  Mol Med       Date:  1999-01       Impact factor: 6.354

Review 2.  DNA and RNA-based vaccines: principles, progress and prospects.

Authors:  W W Leitner; H Ying; N P Restifo
Journal:  Vaccine       Date:  1999-12-10       Impact factor: 3.641

Review 3.  The promise of nucleic acid vaccines.

Authors:  N P Restifo; H Ying; L Hwang; W W Leitner
Journal:  Gene Ther       Date:  2000-01       Impact factor: 5.250

4.  Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization.

Authors:  Fateme Sadri-Ardalani; Mahdi Shabani; Mohammad Mehdi Amiri; Motahareh Bahadori; Shaghayegh Emami; Ali Reza Sarrafzadeh; Farzaneh Noutash-Haghighat; Mahmood Jeddi-Tehrani; Fazel Shokri
Journal:  Tumour Biol       Date:  2015-08-19

5.  Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.

Authors:  Håkan Norell; Isabel Poschke; Jehad Charo; Wei Z Wei; Courtney Erskine; Marie P Piechocki; Keith L Knutson; Jonas Bergh; Elisabet Lidbrink; Rolf Kiessling
Journal:  J Transl Med       Date:  2010-06-07       Impact factor: 5.531

Review 6.  Antigen-specific immunotherapy of cervical and ovarian cancer.

Authors:  Chien-Fu Hung; T C Wu; Archana Monie; Richard Roden
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

7.  Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.

Authors:  Claudia Curcio; Emma Di Carlo; Raphael Clynes; Mark J Smyth; Katia Boggio; Elena Quaglino; Michela Spadaro; Mario P Colombo; Augusto Amici; Pier-Luigi Lollini; Piero Musiani; Guido Forni
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

8.  Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.

Authors:  Michael J Campbell; Wendy S Wollish; Margaret Lobo; Laura J Esserman
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-06       Impact factor: 2.416

Review 9.  Pre-clinical applications of transgenic mouse mammary cancer models.

Authors:  C J Kavanaugh; K V Desai; A Calvo; P H Brown; C Couldrey; R Lubet; J E Green
Journal:  Transgenic Res       Date:  2002-12       Impact factor: 2.788

10.  The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity.

Authors:  Alexios Dimitriadis; Chrysanthi Gontinou; Constantin N Baxevanis; Avgi Mamalaki
Journal:  BMC Cancer       Date:  2009-10-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.